Bhardwaj, A.
In silico multi subunit vaccine design referring spike glycoprotein of SARS-COV-2 (covid–19): the world pandemic - Vol.83(1), Jan-Feb - Mumbai Indian Journal of Pharmaceutical Science 2021 - 21-31p.
Contagious human coronavirus belong to family Coronaviridae and infects human respiratory system
causing the disease known as COVID-19 (World Health Organization). To eradicate the severe acute
respiratory syndrome coronavirus 2 pandemic, an effective vaccine should be developed. In the current
study immunoinformatics procedures were employed to introduce a novel multi-epitope subunit vaccine.
This multi-epitope vaccine can activate equally class I and II human leukocyte antigen and antibody
mediated immune responses. Spike glycoprotein (protein data bank Id: 6VSB) of the coronavirus was
selected and analysed using immune epitope database server for prediction of potential immunogenic B
and T-cell epitopes. Population conservation studies of the selected protein and predicted epitopes were
also performed using population conservancy analysis tool of immune epitope database resource. The two
dimensional and three dimensional structure of multi-epitope vaccine were predicted and authenticated
using PROCheck and Raptor-X servers. Docking results of the multi-epitope vaccine peptide with human
leukocyte antigen class I and II alleles predicted ef ficient binding and the resulted docked models were
stable during simulation. In silico immune evaluation using C-ImmSim server showed that the peptide
could concurrently elicit cell-mediated and humoral immune responses. Immune simulation studies
significantly anticipated high levels of Immunoglobulin M and Immunoglobulin M, T-helper, T-cytotoxic
cells, Interferon-γ.
PHARMACEUTICS
In silico multi subunit vaccine design referring spike glycoprotein of SARS-COV-2 (covid–19): the world pandemic - Vol.83(1), Jan-Feb - Mumbai Indian Journal of Pharmaceutical Science 2021 - 21-31p.
Contagious human coronavirus belong to family Coronaviridae and infects human respiratory system
causing the disease known as COVID-19 (World Health Organization). To eradicate the severe acute
respiratory syndrome coronavirus 2 pandemic, an effective vaccine should be developed. In the current
study immunoinformatics procedures were employed to introduce a novel multi-epitope subunit vaccine.
This multi-epitope vaccine can activate equally class I and II human leukocyte antigen and antibody
mediated immune responses. Spike glycoprotein (protein data bank Id: 6VSB) of the coronavirus was
selected and analysed using immune epitope database server for prediction of potential immunogenic B
and T-cell epitopes. Population conservation studies of the selected protein and predicted epitopes were
also performed using population conservancy analysis tool of immune epitope database resource. The two
dimensional and three dimensional structure of multi-epitope vaccine were predicted and authenticated
using PROCheck and Raptor-X servers. Docking results of the multi-epitope vaccine peptide with human
leukocyte antigen class I and II alleles predicted ef ficient binding and the resulted docked models were
stable during simulation. In silico immune evaluation using C-ImmSim server showed that the peptide
could concurrently elicit cell-mediated and humoral immune responses. Immune simulation studies
significantly anticipated high levels of Immunoglobulin M and Immunoglobulin M, T-helper, T-cytotoxic
cells, Interferon-γ.
PHARMACEUTICS